Everbright Securities has released a research report noting that Moderna and Merck have jointly announced positive Phase 3 trial results for their personalized mRNA cancer vaccine, Intismeran autogene, in melanoma. From a research and development perspective, the expansion from infectious diseases to oncology underscores the importance of a company's technology transferability, which primarily includes algorithms for neoantigen sequence selection and delivery systems that optimize targeting and overcome patent barriers. As the commercial value of mRNA vaccines continues to rise, the research house believes that upstream suppliers in the industry chain are well-positioned to benefit over the long term.

Successful Phase 3 Melanoma Trial Reshapes the Commercial Value of mRNA Vaccines

Intismeran is an individualized mRNA cancer vaccine encapsulated in lipid nanoparticles that encodes 34 patient-specific tumor neoantigens. Its clinical study, INTerpath-001, is a randomized, double-blind, global Phase 3 trial that enrolled 1,137 high-risk melanoma patients (Stages IIB to IV) who had undergone complete surgical resection. Previously, five-year follow-up data from the Phase 2b trial had already demonstrated encouraging efficacy, with a recurrence-free survival hazard ratio of 0.51 when combined with Keytruda compared to Keytruda alone. The latest Phase 3 results further corroborate this efficacy signal. Everbright Securities believes that the success of this Phase 3 trial confirms that mRNA vaccines are not limited to infectious diseases, completing the "from zero to one" proof of concept for mRNA cancer vaccines. This achievement opens up expansion opportunities across multiple cancer types and reshapes the commercial value of the mRNA vaccine technology platform.

Catalysts Ahead: 2027 Could Mark the First Year of mRNA Cancer Vaccine Commercialization

According to Moderna's management outlook, if the interim data from the melanoma Phase 3 trial remains positive, Intismeran could reach the market by 2027. Additionally, mRNA-4359, which targets first- and second-line metastatic melanoma as well as first-line non-small cell lung cancer, is expected to launch by 2028. Other clinical studies for Intismeran include a Phase 2 trial in renal cell carcinoma, with readouts anticipated in 2026 or 2027, and a Phase 2 trial in muscle-invasive bladder cancer, with readouts expected in 2027. Overseas mRNA vaccine leader BioNTech also has multiple catalysts on the horizon: the personalized vaccine Autogene, with a Phase 2 study in adjuvant colorectal cancer expected to complete its final analysis in 2027, and the off-the-shelf vaccine BNT113, with a Phase 3 study in first-line HPV16+ head and neck squamous cell carcinoma expected to complete its interim analysis in 2026.

R&D Focus: Assessing Technology Transferability from Infectious Diseases to Cancer Vaccines

Domestic companies with mRNA cancer vaccine pipelines in development include CSPC Pharmaceutical Group, CanSino Biologics, Hengrui Medicine, and Yundun Pharma, among others, with some already possessing experience in developing anti-infective mRNA vaccines. As the field expands from infectious diseases to oncology, Everbright Securities emphasizes the need to evaluate a company's technology transferability, particularly in terms of algorithms for neoantigen sequence screening and delivery systems that enhance targeting and navigate patent hurdles.

"Water Sellers": Upstream Raw Materials and Midstream CXO Players Stand to Gain

In the near term, Everbright Securities views Moderna's Phase 3 results as a validation of the mechanism for mRNA cancer vaccines, which could help revive financing activity among biotech firms in this space. Over the medium to long term, mRNA cancer vaccines may expand from immunologically sensitive tumor types, such as non-small cell lung cancer, bladder cancer, and renal cell carcinoma, to immunologically insensitive types, including pancreatic and gastric cancers. As the commercial value of mRNA vaccines is redefined, the "water sellers" along the industry chain are expected to reap sustained benefits.

Risk Analysis

Key risks include the potential for disappointing Phase 3 clinical results, slower-than-expected product commercialization, delays in indication expansion, intensifying industry competition, and geopolitical uncertainties.